The 20Sense Report

A quarterly publication that elevates the specialty conversation through the sharing of innovative ideas, best practices, challenges and opportunities.

20Sense Issue 30
20Sense Issue 29: understanding patient registries in Canada
20Sense Issue 28: Change makers in Canadian specialty healthcare
20Sense Issue 27: artificial intelligence and specialty healthcare in Canada
20Sense Issue 26: has managed access arrived in Canada?
20Sense Issue 24: REAL-WORLD DATA FROM PATIENT SUPPORT PROGRAMS IN CANADA:
Issue 20: specialty medicine and private payers
Issue 19: Do better? yes, we can
issue 18: Oncology treatment today
Issue 17: Rare diseases and conditions in Canada
Issue 16: Outcomes-based agreements in Canada
Issue 15: The biologic plot thickens
Issue 14: From patients for patients
Issue 13: behind the scenes of a pandemic
Issue 12: Data surge ahead
Issue 11: Patient support programs; a tsunami is rolling in
Issue 10: At the heart of it all; the specialty pharma patient
Issue 9: Are we ready to put health outcomes data to work?
Issue 8: The innovation vs sustainability conundrum
Issue 7: Wanted: more and better specialty data
Issue 6: Patients are talking. Are we listening?
Issue 5: A broken system: the ongoing saga of originator biologics and biosimilars
Issue 4: Oncology medications just got simpler…or did they?
Issue 3: Biosimilars and Patient Support, a Must-Have Combination
Issue 2: The Hidden Value of Patient Support Programs
Issue 1: Joint Value Creation, Innovation and Operational Excellence Required
20Sense Back to Basics: Specialty Pharmaceuticals & Patient Support Programs

Thanks to The 20Sense Report sponsors, supporting independently researched content and working together to provide value and transparency within Canada’s specialty pharmaceutical industry.

20sense sponsors